For example the nucleoside drug didanosine

rabbirh001@gmai

The fifth edition can be roughly preicte the release time of the handbook is estimate to be between 2019 and 2020 2. The motivation for changing the drugs include in the manual. The changes in the drug list mainly come from two reasons one is that the old drugs have greater clinical side effects and at the same time new drugs are substitute in a large range of categories; the other is the approval of the import of new drugs. was remove from the list due to severe pancreatitis toxicity and other side effects. For the same reason the nonnucleoside drug indinavir was replaced by kaletra Domestic drugs and importe drugs in the free drug list in the handbook.

It can be seen from the change process of the manual in the past  France WhatsApp Number Data dynasties that the importe drugs in the free drug list have experience a process from scratch. For example all 6 free drugs in the first eition of the manual are domestically produce and 3 of the 9 free drugs in the second eition are importe. However as drug patents expire and patent restrictions are relaxe some importe drugs will gradually become domestically produce. For example 4 of the 8 free drugs in the third eition of the handbook are importe drugs tenofovir abacavir efavirenz and kaletra and 8 of the 8 free drugs in the fourth eition of the handbook are free. Two of the drugs are importe abacavir and kaletra while tenofovir and efavirenz are domestically produce domestic firstline free drug program tiragil combination all three drugs have been domestically produce 4.

Determination of free drugs in the manual. Free drugs are the basic treatment guarantee provide by the state for domestic infecte people ensuring that all infecte people can benefit from the four frees and one care policy and receive normal antiviral treatment. Therefore free meicine is of a baseline nature. Taking into account the emergence of drug resistance free drugs should also be able to form first and secondline drug regimens. This means that free drugs must cover at least three drug categories. Under the condition of controlling costs in addition to nucleoside drugs free drugs are also guarantee to be available among non nucleoside drugs and protease inhibitors free drugs are actually obtaine by the state from pharmaceutical companies through the volume of price method.